Bevacizumab 2 — Class III drug recall D-0531-2023
Terminated recall by Pine Pharmaceuticals, LLC, reported 2023-04-19, distributed nationwide. Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
| Recall number | D-0531-2023 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pine Pharmaceuticals, LLC, Tonawanda, NY, United States |
| Recall initiated | 2023-03-27 |
| Classified | 2023-04-13 |
| Reported by FDA | 2023-04-19 |
| Terminated | 2023-06-01 |
| Distributed | Nationwide (US) |
| Quantity | 932 syringes |
| Reason classes | labeling |
| NDC | 69194-0458-01 |
| Lot numbers | 66316, 66377 |
| Expiration dates | 2023-06-28 |
Product
Bevacizumab 2.5 mg/0.1 mL, Solution for Injection in 1mL, silicone free slip tip syringe, each Syringe supplied in individually labeled poly envelopes (primary packaging). Repackaged by Pine Pharmaceuticals, Pine Pharmaceuticals 355 Riverwalk Parkway, Tonawanda, NY 14150, Office Use Only, Not for Resale. Secondary packaging consists of a coated cardboard box, with order-specific label indicating lot number housed within order/container. NDC # 69194-0458-1
Reason for recall
Labeling: Incorrect or Missing Lot and/or Exp Date: Lot code on primary packaging is incorrect.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0531-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.